Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)

Trial Profile

An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Adult attention Deficit Hyperactivity Disorder (ADHD) Borderline Personality Disorder (BPD), Autism Spectrum Disorder (ASD)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vafidemstat (Primary)
  • Indications Aggression
  • Focus Adverse reactions; First in man
  • Acronyms REIMAGINE
  • Sponsors Oryzon
  • Most Recent Events

    • 03 Oct 2019 Results presented in the Oryzon media release.
    • 03 Oct 2019 According to an Oryzon media release, aggregated data from the three different cohorts of psychiatric patients (attention deficit hyperactivity disorder (ADHD), autistic spectrum disorder (ASD) and borderline personality disorder (BPD)) in this trial were presented at the 2019 International College of Neuropsychopharmacology (CINP) meeting in Athens, Greece.
    • 23 Sep 2019 According to an Oryzon media release, additional safety and clinical efficacy data from this trial will be presented at the International Conference on Neuropsychopharmacology, CINP 2019, to be held on October 3 to 5 in Athens,Greece.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top